Quantitative Research

Page 1 of 1
Quantitative Equity Report | Release Date: 18 September 2015 | Reporting Currency: EUR | Trading Currency: EUR
Laboratorio Reig Jofre SA RJF
Last Close
Quantitative Fair Value Estimate
Market Cap (Mil)
Sector
0.21
0.25
264.6
d Healthcare
Laboratorio Reig Jofre SA is engaged in the development of
prescription and non-prescription pharmaceutical products,
medical devices, nutritional supplements and consumer
healthcare products.
Industry
Country of Domicile
Drug Manufacturers - Specialty ESP Spain
& Generic
Price Versus Quantitative Fair Value
2011
2012
2013
2014
2015
2016
Sales/Share
Forecast Range
Forcasted Price
Dividend
Split
Quantitative Fair Value Estimate
10
Total Return
Quantitative Scores
8
Scores
Momentum:
—
Standard Deviation: 55.37
All Rel Sector Rel Country
Quantitative Moat
None
Valuation
Undervalued
Quantitative Uncertainty Very High
Financial Health
Moderate
53
55
73
45
62
52
74
26
6
37
73
57
32
4
0.17
52-Wk
0.46
0.10
5-Yr
0.46
2
RJF
d
ESP
Undervalued
Fairly Valued
Overvalued
Valuation
Sector
Median
Country
Median
0.92
41.9
—
186.7
1.1
—
1.0
2.0
0.85
27.7
13.4
18.7
27.3
1.48
3.4
4.0
0.92
16.6
13.5
8.6
16.4
2.79
1.5
1.2
Current 5-Yr Avg
Sector
Median
Country
Median
12.4
6.5
300.9
9.5
3.2
279.9
Current 5-Yr Avg
Price/Quant Fair Value
Price/Earnings
Forward P/E
Price/Cash Flow
Price/Free Cash Flow
Dividend Yield %
Price/Book
Price/Sales
0.85
1.2
—
—
—
—
2.2
0.6
Profitability
Return on Equity %
Return on Assets %
Revenue/Employee (K)
10.7
8.0
146.2
-0.2
0.4
226.6
Score
100
Quantitative Moat
80
60
40
20
0
2008
2009
2010
2011
2012
2013
2014
Financial Health
Current 5-Yr Avg
Distance to Default
Solvency Score
Assets/Equity
Long-Term Debt/Equity
2015
Sector
Median
Country
Median
0.6
510.5
1.4
0.1
0.6
608.5
2.7
0.4
0.5
—
1.5
0.0
0.5
—
1.6
0.1
1-Year
3-Year
5-Year
10-Year
85.0
156.5
5,898.2
—
-59.8
-11.8
25.3
—
52.7
—
-29.1
17.1
-15.5
—
—
—
-19.9
-7.8
9.6
5.0
26.7
—
-2.2
-14.5
Growth Per Share
Revenue %
Operating Income %
Earnings %
Dividends %
Book Value %
Stock Total Return %
-53.6
-39.6
-17.3
-35.0
151.2
135.7
-35.9
-32.2
14.1
16.4
—
-2.3
1.5
—
-10,000.0
1.4
12.89
38.5
2.9
—
45.9
7.5
—
1.2
0.6
Total Return %
+/– Market (Morningstar World
Index)
Dividend Yield %
Price/Earnings
Price/Revenue
Undervalued
Fairly Valued
Overvalued
Monthly Volume (Thousand Shares)
Liquidity: High
8,659
Financials (Fiscal Year in K)
Revenue
% Change
2010
2011
2012
2013
2014
TTM
38,841
-71.1
29,485
-24.1
29,926
1.5
31,370
4.8
58,036
85.0
121,494
109.3
-19,166
—
-22,618
-16,676
—
16,066
128
—
-6
2,014
1,473.4
953
5,165
156.4
4,833
11,786
128.2
10,788
-5,024
-988
-6,012
-15.5
-7,110
-641
-7,751
-26.3
-5,892
-486
-6,378
-21.3
396
-482
-86
-0.3
—
—
—
—
396
-482
-86
-0.1
Operating Cash Flow
Capital Spending
Free Cash Flow
% Sales
-0.07
—
-0.09
0.05
—
-0.02
0.00
-100.0
-0.02
0.00
—
-0.01
0.18
5,822.7
0.00
0.18
1.3
0.00
EPS
% Change
Free Cash Flow/Share
—
0.37
329
—
0.23
329
—
0.26
324
0.04
0.24
1,260
0.00
0.06
—
0.00
0.10
1,260
-27.1
-11.8
-58.2
0.20
2.5
20.1
9.2
54.5
0.17
1.9
0.0
0.0
0.0
0.23
1.1
1.2
1.1
3.0
0.35
1.1
5.0
3.7
8.3
0.44
1.5
10.7
8.0
8.9
0.90
1.5
Profitability
Return on Equity %
Return on Assets %
Net Margin %
Asset Turnover
Financial Leverage
73.2
-49.3
205
83.3
-56.6
17,656
73.1
0.4
0
73.9
6.4
—
64.7
8.9
5,806
62.9
9.7
5,167
Gross Margin %
Operating Margin %
Long-Term Debt
73,354
11.4
86,590
62.1
86,753
99.9
75,617
135.2
118,144
4.8
125,130
9.4
Quarterly Revenue & EPS
Revenue (K)
Mar
Jun
2015
42,999.0 38,194.6
2014
10,096.0 7,640.0
2013
10,741.0 7,418.0
2012
9,466.0 7,393.0
Earnings Per Share
2015
0.00
0.00
2014
0.01
0.00
2013
0.01
0.00
2012
0.01
-0.04
Operating Income
% Change
Net Income
Dividends/Share
Book Value/Share
Shares Outstanding (Mil)
Total Equity
Fixed Asset Turns
Revenue Growth Year On Year %
Sep
Dec
Total
—
—
—
7,016.0 33,284.4 58,036.4
7,143.0 6,068.0 31,370.0
6,732.0 13,067.0 29,926.0
—
0.00
0.00
0.03
—
0.17
0.00
0.03
—
0.18
0.00
0.00
448.5
399.9
325.9
0.3
6.1
3.0
-53.6
2013
-6.0
2014
©2015 Morningstar. All Rights Reserved. Unless otherwise provided in a separate agreement, you may use this report only in the country in which its original distributor is based. Data as originally reported. The information
contained herein is not represented or warranted to be accurate, correct, complete, or timely. This report is for information purposes only, and should not be considered a solicitation to buy or sell any security. Redistribution
is prohibited without written permission. To order reprints, call +1 312-696-6100. To license the research, call +1 312-696-6869.
-1.8
2015
®
ß